Drug Studies on Rett Syndrome: From Bench to Bedside

Abdala, A. P., Dutschmann, M., Bissonnette, J. M., & Paton, J. F. (2010). Correction of respiratory disorders in a mouse model of Rett syndrome. Proceedings of the National Academy of Sciences of the United States of America. https://doi.org/10.1073/pnas.1012104107.PubMedPubMedCentralCrossRef

Abdala, A. P., Lioy, D. T., Garg, S. K., Knopp, S. J., Paton, J. F. R., & Bissonnette, J. M. (2014). Effect of Sarizotan, a 5-HT1a and D2-like receptor agonist, on respiration in three mouse models of Rett syndrome. American Journal of Respiratory Cell and Molecular Biology,50(6), 1031–1039. https://doi.org/10.1165/rcmb.2013-0372OC.PubMedPubMedCentralCrossRef

Arai, A., & Kessler, M. (2007). Pharmacology of ampakine modulators: From AMPA receptors to synapses and behavior. Current Drug Targets,8(5), 583–602.PubMedCrossRef

Balachandar, V., Dhivya, V., Gomathi, M., Mohanadevi, S., Venkatesh, B., Geetha, B. (2016). A review of Rett syndrome (RTT) with induced pluripotent stem cells. Stem Cell Investigation, 3, 52. https://doi.org/10.21037/sci.2016.09.05

Ben-Zeev, B., Aharoni, R., Nissenkorn, A., & Arnon, R. (2011). Glatiramer acetate (GA, Copolymer-1) an hypothetical treatment option for Rett syndrome. Medical Hypotheses,76(2), 190–193.PubMedCrossRef

Bharathi, G., Venugopal, A., & Vellingiri, B. (2019). Music therapy as a therapeutic tool in improving the social skills of autistic children. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery,55(1), 44. https://doi.org/10.1186/s41983-019-0091-x.CrossRef

Biohaven Pharmaceutical Holding Company Ltd. (n.d.). Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA Antagonist. PR Newswire. 2018. https://www.prnewswire.com/news-releases/biohaven-announces-initiation-of-clinical-development-for-bhv-5000-a-novel-low-trapping-nmda-antagonist-300584389.html (Accessed on Feb 6, 2019). NEW HAVEN, Conn. https://www.prnewswire.com/news-releases/biohaven-announces-initiation-of-clinical-development-for-bhv-5000-a-novel-low-trapping-nmda-antagonist-300584389.html. Accessed 6 Feb 2019

Bittolo, T., Raminelli, C. A., Deiana, C., Baj, G., Vaghi, V., Ferrazzo, S., et al. (2016). Pharmacological treatment with mirtazapine rescues cortical atrophy and respiratory deficits in MeCP2 null mice. Scientific Reports,6, 19796.PubMedPubMedCentralCrossRef

Brendel, C., Klahold, E., Gärtner, J., & Huppke, P. (2009). Suppression of nonsense mutations in Rett syndrome by aminoglycoside antibiotics. Pediatric Research,65(5), 520.PubMedCrossRef

Brendel, C., Belakhov, V., Werner, H., Wegener, E., Gärtner, J., Nudelman, I., et al. (2011). Readthrough of nonsense mutations in Rett syndrome: Evaluation of novel aminoglycosides and generation of a new mouse model. Journal of Molecular Medicine,89(4), 389–398.PubMedCrossRef

Buchovecky, C. M., Turley, S. D., Brown, H. M., Kyle, S. M., McDonald, J. G., Liu, B., et al. (2013). A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome. Nature Genetics,45(9), 1013–1020. https://doi.org/10.1038/ng.2714.PubMedPubMedCentralCrossRef

Castro, J., Garcia, R. I., Kwok, S., Banerjee, A., Petravicz, J., Woodson, J., et al. (2014). Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett syndrome. Proceedings of the National Academy of Sciences,111(27), 9941.CrossRef

Chahrour, M., Jung, S. Y., Shaw, C., Zhou, X., Wong, S. T., Qin, J., et al. (2008). MeCP2, a key contributor to neurological disease, activates and represses transcription. Science,320(5880), 1224–1229.PubMedPubMedCentralCrossRef

Chapleau, C. A., Lane, J., Pozzo-Miller, L., & Percy, A. K. (2013). Evaluation of current pharmacological treatment options in the management of Rett syndrome: From the present to future therapeutic alternatives. Current Clinical Pharmacology,8(4), 358–369.PubMedPubMedCentralCrossRef

Chin, E. W. M., Marcy, G., Yoon, S.-I., Ma, D., Rosales, F. J., Augustine, G. J., et al. (2016). Choline ameliorates disease phenotypes in human iPSC models of Rett syndrome. Neuromolecular Medicine,18(3), 364–377. https://doi.org/10.1007/s12017-016-8421-y.PubMedCrossRef

Chin, E. W. M., Lim, W. M., Ma, D., Rosales, F. J., & Goh, E. L. K. (2019). Choline rescues behavioural deficits in a mouse model of Rett syndrome by modulating neuronal plasticity. Molecular Neurobiology,56(6), 3882–3896. https://doi.org/10.1007/s12035-018-1345-9.PubMedCrossRef

De Filippis, B., Fabbri, A., Simone, D., Canese, R., Ricceri, L., Malchiodi-Albedi, F., et al. (2012). Modulation of RhoGTPases improves the behavioral phenotype and reverses astrocytic deficits in a mouse model of Rett syndrome. Neuropsychopharmacology,37(5), 1152–1163. https://doi.org/10.1038/npp.2011.301.PubMedCrossRef

De Filippis, B., Ricceri, L., Fuso, A., & Laviola, G. (2013). Neonatal exposure to low dose corticosterone persistently modulates hippocampal mineralocorticoid receptor expression and improves locomotor/exploratory behaviour in a mouse model of Rett syndrome. Neuropharmacology,68, 174–183. https://doi.org/10.1016/j.neuropharm.2012.05.048.PubMedCrossRef

De Filippis, B., Nativio, P., Fabbri, A., Ricceri, L., Adriani, W., Lacivita, E., et al. (2014). Pharmacological stimulation of the brain serotonin receptor 7 as a novel therapeutic approach for Rett syndrome. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 39(11), 2506–2518.https://doi.org/10.1038/npp.2014.105

De Filippis, B., Valenti, D., Chiodi, V., Ferrante, A., de Bari, L., Fiorentini, C., et al. (2015a). Modulation of Rho GTPases rescues brain mitochondrial dysfunction, cognitive deficits and aberrant synaptic plasticity in female mice modeling Rett syndrome. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology,25(6), 889–901. https://doi.org/10.1016/j.euroneuro.2015.03.012.CrossRef

De Filippis, B., Valenti, D., de Bari, L., De Rasmo, D., Musto, M., Fabbri, A., et al. (2015b). Mitochondrial free radical overproduction due to respiratory chain impairment in the brain of a mouse model of Rett syndrome: Protective effect of CNF1. Free Radical Biology & Medicine,83, 167–177. https://doi.org/10.1016/j.freeradbiomed.2015.02.014.CrossRef

Delépine, C., Meziane, H., Nectoux, J., Opitz, M., Smith, A. B., Ballatore, C., et al. (2016). Altered microtubule dynamics and vesicular transport in mouse and human MeCP2-deficient astrocytes. Human Molecular Genetics,25(1), 146–157. https://doi.org/10.1093/hmg/ddv464.PubMedCrossRef

Deogracias, R., Yazdani, M., Dekkers, M. P., Guy, J., Ionescu, M. C. S., Vogt, K. E., et al. (2012). Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proceedings of the National Academy of Sciences,109(35), 14230–14235.CrossRef

Djukic, A., Holtzer, R., Shinnar, S., Muzumdar, H., Rose, S. A., Mowrey, W., et al. (2016). Pharmacologic treatment of Rett syndrome with glatiramer acetate. Pediatric Neurology,61, 51–57. https://doi.org/10.1016/j.pediatrneurol.2016.05.010.PubMedCrossRef

Edison Pharmaceuticals. (n.d.). Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome. PR Newswire. 2014. https://www.prnewswire.com/news-releases/edison-pharmaceuticals-announces-phase-2-positive-clinical-results-for-epi-743-in-rett-syndrome-273691331.html (Accessed on Feb 6, 2019). MOUNTAIN VIEW, California, US. https://www.prnewswire.com/news-releases/edison-pharmaceuticals-announces-phase-2-positive-clinical-results-for-epi-743-in-rett-syndrome-273691331.html. Accessed 4 Jan 2019

Ehinger, Y., Matagne, V., Villard, L., Roux, J.-C. (2018). Rett syndrome from bench to bedside: Recent advances. F1000Research, 7, 398. https://doi.org/10.12688/f1000research.14056.1

El-Khoury, R., Panayotis, N., Matagne, V., Ghata, A., Villard, L., & Roux, J.-C. (2014). GABA and glutamate pathways are spatially and developmentally affected in the brain of Mecp2-deficient mice. PLoS ONE. https://doi.org/10.1371/journal.pone.0092169.PubMedPubMedCentralCrossRef

Ellaway, C., & Christodoulou, J. (2001). Rett syndrome: Clinical characteristics and recent genetic advances. Disability and Rehabilitation,23(3–4), 98–106.PubMed

Ellaway, C. J., Sholler, G., Leonard, H., & Christodoulou, J. (1999). Prolonged QT interval in Rett syndrome. Archives of Disease in Childhood,80(5), 470–472.PubMedPubMedCentralCrossRef

Freilinger, M., Dunkler, D., Lanator, I., Item, C. B., Mühl, A., Fowler, B., et al. (2011). Effects of creatine supplementation in Rett syndrome: A randomized, placebo-controlled trial. Journal of Developmental and Behavioral Pediatrics: JDBP,32(6), 454–460. https://doi.org/10.1097/DBP.0b013e31822177a8.PubMedCrossRef

Gadalla, K. K., Bailey, M. E., Spike, R. C., Ross, P. D., Woodard, K. T., Kalburgi, S. N., et al. (2013). Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. Molecular Therapy,21(1), 18–30.PubMedCrossRef

Garg, S. K., Lioy, D. T., Cheval, H., McGann, J. C., Bissonnette, J. M., Murtha, M. J., et al. (2013). Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome. Journal of Neuroscience,33(34), 13612–13620.PubMedCrossRef

Giampietro, P. F., Schowalter, D. B., Merchant, S., Campbell, L. R., Swink, T., & Roa, B. B. (2006). Widened clinical spectrum of the Q128P MECP2 mutation in Rett syndrome. Child’s Nervous System: ChNS: Official Journal of the International Society for Pediatric Neurosurgery,22(3), 320–324. https://doi.org/10.1007/s00381-005-1155-z.CrossRef

Gibson, J. H., Slobedman, B., Kaipananickal, H., Williamson, S. L., Minchenko, D., El-Osta, A., et al. (2010). Downstream targets of methyl CpG binding protein 2 and their abnormal expression in the frontal cortex of the human Rett syndrome brain. BMC Neuroscience,11(1), 53. https://doi.org/10.1186/1471-2202-11-53.PubMedPubMedCentralCrossRef

Glaze, D. G., Neul, J. L., Percy, A., Feyma, T., Beisang, A., Yaroshinsky, A., et al. (2017). A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome. Pediatric Neurology,76, 37–46. https://doi.org/10.1016/j.pediatrneurol.2017.07.002.PubMedCrossRef

Glaze, D. G., Percy, A. K., Motil, K. J., Lane, J. B., Isaacs, J. S., Schultz, R. J., et al. (2009). A study of the treatment of Rett syndrome with folate and betaine. Journal of Child Neurology, 24(5), 551–556. https://doi.org/10.1177/0883073808327827.PubMedPubMedCentralCrossRef

Gogliotti, R. G., Senter, R. K., Rook, J. M., Ghoshal, A., Zamorano, R., Malosh, C., et al. (2016). mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. Human Molecular Genetics,25(10), 1990–2004. https://doi.org/10.1093/hmg/ddw074.PubMedPubMedCentralCrossRef

Gogliotti, R. G., Senter, R. K., Fisher, N. M., Adams, J., Zamorano, R., Walker, A. G., et al. (2017). mGlu7 potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aai7459.PubMedPubMedCentralCrossRef

Gökben, S., Ardıç, U. A., & Serdaroğlu, G. (2012). Use of buspirone and fluoxetine for breathing problems in Rett syndrome. Pediatric Neurology,46(3), 192–194. https://doi.org/10.1016/j.pediatrneurol.2011.12.003.PubMedCrossRef

Gold, W. A., & Christodoulou, J. (2015). The utility of next-generation sequencing in gene discovery for mutation-negative patients with Rett syndrome. Frontiers in Cellular Neuroscience. https://doi.org/10.3389/fncel.2015.00266.PubMedPubMedCentralCrossRef

Goldmann, T., Overlack, N., Möller, F., Belakhov, V., van Wyk, M., Baasov, T., et al. (2012). A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation. EMBO Molecular Medicine,4(11), 1186–1199.PubMedPubMedCentralCrossRef

Gomathi, M., & Balachandar, V. (2017). Novel therapeutic approaches: Rett syndrome and human induced pluripotent stem cell technology. Stem Cell Investigation,4, 20.PubMedPubMedCentralCrossRef

Gonzales, M. L., & LaSalle, J. M. (2010). The role of MeCP2 in brain development and neurodevelopmental disorders. Current Psychiatry Reports,12(2), 127–134.PubMedPubMedCentralCrossRef

Goyal, M., O’Riordan, M. A., & Wiznitzer, M. (2004). Effect of topiramate on seizures and respiratory dysrhythmia in Rett syndrome. Journal of Child Neurology,19(8), 588–591. https://doi.org/10.1177/088307380401900804.PubMedCrossRef

Guideri, F., & Acampa, M. (2005). Sudden death and cardiac arrhythmias in Rett syndrome. Pediatric Cardiology,26(1), 111. https://doi.org/10.1007/s00246-004-0701-x.PubMedCrossRef

Guo, W., Tsujimura, K., Otsuka, I., & M., Irie, K., Igarashi, K., Nakashima, K., & Zhao, X., (2014). VPA alleviates neurological deficits and restores gene expression in a mouse model of Rett syndrome. PLoS ONE,9(6), e100215. https://doi.org/10.1371/journal.pone.0100215.PubMedPubMedCentralCrossRef

Halbach, N. S., Smeets, E. E., Bierau, J., Keularts, I. M., Plasqui, G., Julu, P. O., et al. (2012). Altered carbon dioxide metabolism and creatine abnormalities in rett syndrome. JIMD Rep. https://doi.org/10.1007/8904_2011_76.PubMedCrossRef

Herrera, J. A., Ward, C. S., Pitcher, M. R., Percy, A. K., Skinner, S., Kaufmann, W. E., et al. (2015). Treatment of cardiac arrhythmias in a mouse model of Rett syndrome with Na+-channel-blocking antiepileptic drugs. Disease Models & Mechanisms,8(4), 363–371. https://doi.org/10.1242/dmm.020131.CrossRef

Hirofuji, S., Hirofuji, Y., Kato, H., Masuda, K., Yamaza, H., Sato, H., et al. (2018). Mitochondrial dysfunction in dopaminergic neurons differentiated from exfoliated deciduous tooth-derived pulp stem cells of a child with Rett syndrome. Biochemical and Biophysical Research Communications,498(4), 898–904.PubMedCrossRef

Hung, S. S. C., Khan, S., Lo, C. Y., Hewitt, A. W., & Wong, R. C. B. (2017). Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases. Pharmacology & Therapeutics,177, 32–43. https://doi.org/10.1016/j.pharmthera.2017.02.026.CrossRef

Janc, O. A., & Müller, M. (2014). The free radical scavenger Trolox dampens neuronal hyperexcitability, reinstates synaptic plasticity, and improves hypoxia tolerance in a mouse model of Rett syndrome. Frontiers in Cellular Neuroscience,8, 56. https://doi.org/10.3389/fncel.2014.00056.PubMedPubMedCentralCrossRef

Janc, O. A., Hüser, M. A., Dietrich, K., Kempkes, B., Menzfeld, C., Hülsmann, S., et al. (2016). Systemic radical scavenger treatment of a mouse model of Rett syndrome: Merits and limitations of the vitamin E derivative trolox. Frontiers in Cellular Neuroscience,10, 266. https://doi.org/10.3389/fncel.2016.00266.PubMedPubMedCentralCrossRef

Jefferson, A., Leonard, H., Siafarikas, A., Woodhead, H., Fyfe, S., Ward, L. M., et al. (2016). Clinical guidelines for management of bone health in Rett syndrome based on expert consensus and available evidence. PLoS ONE,11(2), e0146824. https://doi.org/10.1371/journal.pone.0146824.PubMedPubMedCentralCrossRef

Jin, X., Zhong, W., & Jiang, C. (2013). Time-dependent modulation of GABA(A)-ergic synaptic transmission by allopregnanolone in locus coeruleus neurons of Mecp2-null mice. American Journal of Physiology; Cell Physiology, 305(11), C1151–1160. https://doi.org/10.1152/ajpcell.00195.2013

Johnson, R. A., Lam, M., Punzo, A. M., Li, H., Lin, B. R., Ye, K., et al. (2011). 7, 8-dihydroxyflavone exhibits therapeutic efficacy in a mouse model of Rett syndrome. Journal of Applied Physiology,112(5), 704–710.PubMedPubMedCentralCrossRef

Katz, D. M., Berger-Sweeney, J. E., Eubanks, J. H., Justice, M. J., Neul, J. L., Pozzo-Miller, L., et al. (2012). Preclinical research in Rett syndrome: Setting the foundation for translational success. Disease Models & Mechanisms,5(6), 733–745. https://doi.org/10.1242/dmm.011007.CrossRef

Katz, D. M., Bird, A., Coenraads, M., Gray, S. J., Menon, D. U., Philpot, B. D., et al. (2016). Rett syndrome: Crossing the threshold to clinical translation. Trends in Neurosciences,39(2), 100–113. https://doi.org/10.1016/j.tins.2015.12.008.PubMedPubMedCentralCrossRef

Khwaja, O. S., Ho, E., Barnes, K. V., O’Leary, H. M., Pereira, L. M., Finkelstein, Y., et al. (2014). Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proceedings of the National Academy of Sciences of the United States of America,111(12), 4596–4601. https://doi.org/10.1073/pnas.1311141111.PubMedPubMedCentralCrossRef

Kolb-Kokocinski, A., Mehrle, A., Bechtel, S., Simpson, J. C., Kioschis, P., Wiemann, S., et al. (2006). The systematic functional characterisation of Xq28 genes prioritises candidate disease genes. BMC Genomics,7(1), 29. https://doi.org/10.1186/1471-2164-7-29.PubMedPubMedCentralCrossRef

Kozikowski, A. P., Shen, S., Pardo, M., Tavares, M. T., Szarics, D., Benoy, V., et al. (2019). Brain penetrable histone deacetylase 6 inhibitor SW-100 ameliorates memory and learning impairments in a mouse model of fragile X syndrome. ACS Chemical Neuroscience, 10(3), 1679–1695. https://doi.org/10.1021/acschemneuro.8b00600.PubMedCrossRef

Krishnan, N., Krishnan, K., Connors, C. R., Choy, M. S., Page, R., Peti, W., et al. (2015). PTP1B inhibition suggests a therapeutic strategy for Rett syndrome. The Journal of Clinical Investigation,125(8), 3163–3177. https://doi.org/10.1172/JCI80323.PubMedPubMedCentralCrossRef

Kron, M., Howell, C. J., Adams, I. T., Ransbottom, M., Christian, D., Ogier, M., & Katz, D. M. (2012). Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 32(40), 13860–13872. https://doi.org/10.1523/JNEUROSCI.2159-12.2012.CrossRef

Kron, M., Lang, M., Adams, I. T., Sceniak, M., Longo, F., & Katz, D. M. (2014). A BDNF loop-domain mimetic acutely reverses spontaneous apneas and respiratory abnormalities during behavioral arousal in a mouse model of Rett syndrome. Disease Models & Mechanisms,7(9), 1047–1055.CrossRef

Kumandas, S., Caksen, H., Ciftçi, A., Oztürk, M., & Per, H. (2001). Lamotrigine in two cases of Rett syndrome. Brain & Development,23(4), 240–242.CrossRef

Lallar, M., Rai, A., Srivastava, P., Mandal, K., Gupta, N., Kabra, M., et al. (2018). Molecular testing of MECP2 gene in Rett syndrome phenotypes in Indian girls. Indian Pediatrics,55(6), 474–477. https://doi.org/10.1007/s13312-018-1336-y.PubMedCrossRef

Landucci, E., Brindisi, M., Bianciardi, L., Catania, L. M., Daga, S., Croci, S., et al. (2018). iPSC-derived neurons profiling reveals GABAergic circuit disruption and acetylated α-tubulin defect which improves after iHDAC6 treatment in Rett syndrome. Experimental Cell Research,368(2), 225–235. https://doi.org/10.1016/j.yexcr.2018.05.001.PubMedCrossRef

Lane, J. B., Salter, A. R., Jones, N. E., Cutter, G., Horrigan, J., Skinner, S. A., et al. (2017). Assessment of caregiver inventory for Rett syndrome. Journal of Autism and Developmental Disorders,47(4), 1102–1112. https://doi.org/10.1007/s10803-017-3034-3.PubMedPubMedCentralCrossRef

Levitt, E. S., Hunnicutt, B. J., Knopp, S. J., Williams, J. T., & Bissonnette, J. M. (2013). A selective 5-HT _1a receptor agonist improves respiration in a mouse model of Rett syndrome. Journal of Applied Physiology,115(11), 1626–1633. https://doi.org/10.1152/japplphysiol.00889.2013.PubMedPubMedCentralCrossRef

Li, W., Bellot-Saez, A., Phillips, M. L., Yang, T., Longo, F. M., & Pozzo-Miller, L. (2017). A small-molecule TrkB ligand restores hippocampal synaptic plasticity and object location memory in Rett syndrome mice. Disease Models & Mechanisms,10(7), 837–845.CrossRef

Liebhaber, G. M., Riemann, E., & Baumeister, F. A. M. (2003). Ketogenic diet in Rett syndrome. Journal of Child Neurology,18(1), 74–75. https://doi.org/10.1177/08830738030180011801.PubMedCrossRef

Liyanage, V. R. B., & Rastegar, M. (2014). Rett syndrome and MeCP2. Neuromolecular Medicine,16(2), 231–264. https://doi.org/10.1007/s12017-014-8295-9.PubMedPubMedCentralCrossRef

Lyst, M. J., & Bird, A. (2015). Rett syndrome: A complex disorder with simple roots. Nature Reviews Genetics,16(5), 261.PubMedCrossRef

Mancini, J., Dubus, J.-C., Jouve, E., Roux, J.-C., Franco, P., Lagrue, E., et al. (2018). Effect of desipramine on patients with breathing disorders in RETT syndrome. Annals of Clinical and Translational Neurology,5(2), 118–127. https://doi.org/10.1002/acn3.468.PubMedCrossRef

Marchetto, M. C. N., Carromeu, C., Acab, A., Yu, D., Yeo, G., & Mu, Y. (2010). A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell. https://doi.org/10.1016/j.cell.2010.10.016.PubMedPubMedCentralCrossRef

Marschik, P. B., Einspieler, C., Oberle, A., Laccone, F., & Prechtl, H. F. R. (2009). Case report: Retracing atypical development: A preserved speech variant of Rett syndrome. Journal of Autism and Developmental Disorders,39(6), 958–961. https://doi.org/10.1007/s10803-009-0703-x.PubMedPubMedCentralCrossRef

Martínez, A. R., Turon, M., Callejón-Póo, L., Sole, E., Armstrong, J., & Pineda, M. (2013). Treatment response in behaviour disorders in Rett syndrome. Journal of Behavioral and Brain Science,03(02), 217–224. https://doi.org/10.4236/jbbs.2013.32023.CrossRef

Mellios, N., Woodson, J., Garcia, R. I., Crawford, B., Sharma, J., Sheridan, S. D., et al. (2014). β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome. Proceedings of the National Academy of Sciences of the United States of America,111(27), 9947–9952. https://doi.org/10.1073/pnas.1309426111.PubMedPubMedCentralCrossRef

Mendhekar, D. N., & Duggal, H. S. (2007). Acquired variant of Rett’s disorder and response to lamotrigine. The Journal of Neuropsychiatry and Clinical Neurosciences,19(4), 474–475. https://doi.org/10.1176/jnp.2007.19.4.474.PubMedCrossRef

Mierau, S. B., Patrizi, A., Hensch, T. K., & Fagiolini, M. (2016). Cell-specific regulation of N-methyl-D-aspartate receptor maturation by Mecp2 in cortical circuits. Biological Psychiatry,79(9), 746–754. https://doi.org/10.1016/j.biopsych.2015.05.018.PubMedCrossRef

Miranda-Lourenço, C., Duarte, S. T., Palminha, C., Colino-Oliveira, M., Jéssica, R., Gomes, R., et al. (2019). Reestablishment of adenosine levels: A possible strategy for Rett Syndrome. Frontiers in Cellular Neuroscience, Conference Abstract: XVI Meeting of the Portuguese Society for Neuroscience (SPN2019). https://doi.org/10.3389/conf.fncel.2019.01.00046

Na, E. S., De Jesús-Cortés, H., Martinez-Rivera, A., Kabir, Z. D., Wang, J., Ramesh, V., et al. (2017). D-Cycloserine improves synaptic transmission in an animal model of Rett syndrome. PLoS ONE,12(8), e0183026. https://doi.org/10.1371/journal.pone.0183026.PubMedPubMedCentralCrossRef

Naegelin, Y., Barde, Y. A., Weber, P., Plecko, B., Datta, A. N., & Kappos, L. (2015). OP24—2321: FINGORETT—An ongoing phase I clinical study to assess safety and efficacy of oral fingolimod (FTY720) in children with Rett syndrome. European Journal of Paediatric Neurology,19, S8. https://doi.org/10.1016/S1090-3798(15)30025-8.CrossRef

Nag, N., & Berger-Sweeney, J. E. (2007). Postnatal dietary choline supplementation alters behavior in a mouse model of Rett syndrome. Neurobiology of Disease,26(2), 473–480. https://doi.org/10.1016/j.nbd.2007.02.003.PubMedCrossRef

Nag, N., Mellott, T. J., & Berger-Sweeney, J. E. (2008). Effects of postnatal dietary choline supplementation on motor regional brain volume and growth factor expression in a mouse model of Rett syndrome. Brain Research,1237, 101–109. https://doi.org/10.1016/j.brainres.2008.08.042.PubMedCrossRef

Nance, E., Kambhampati, S. P., Smith, E. S., Zhang, Z., Zhang, F., Singh, S., et al. (2017). Dendrimer-mediated delivery of N-acetyl cysteine to microglia in a mouse model of Rett syndrome. Journal of Neuroinflammation,14(1), 252. https://doi.org/10.1186/s12974-017-1004-5.PubMedPubMedCentralCrossRef

Nelson, E. D., Kavalali, E. T., & Monteggia, L. M. (2006). MeCP2-dependent transcriptional repression regulates excitatory neurotransmission. Current Biology,16(7), 710–716. https://doi.org/10.1016/j.cub.2006.02.062.PubMedCrossRef

Nissenkorn, A., Kidon, M., & Ben-Zeev, B. (2017). A potential life-threatening reaction to glatiramer acetate in Rett syndrome. Pediatric Neurology,68, 40–43. https://doi.org/10.1016/j.pediatrneurol.2016.11.006.PubMedCrossRef

O’Leary, H. M., Kaufmann, W. E., Barnes, K. V., Rakesh, K., Kapur, K., Tarquinio, D. C., et al. (2018). Placebo-controlled crossover assessment of mecasermin for the treatment of Rett syndrome. Annals of Clinical and Translational Neurology,5(3), 323–332. https://doi.org/10.1002/acn3.533.PubMedPubMedCentralCrossRef

Ogier, M., Wang, H., Hong, E., Wang, Q., Greenberg, M. E., & Katz, D. M. (2007). Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome. Journal of Neuroscience,27(40), 10912–10917.PubMedCrossRef

Ohya, T., Yamashita, Y., & Matsuishi, T. (2005). [Sudden death in Rett syndrome]. Nihon Rinsho. Japanese Journal of Clinical Medicine, 63(7), 1178–1182.

Panighini, A., Duranti, E., Santini, F., Maffei, M., Pizzorusso, T., Funel, N., et al. (2013). Vascular dysfunction in a mouse model of Rett syndrome and effects of curcumin treatment. PLoS ONE,8(5), e64863. https://doi.org/10.1371/journal.pone.0064863.PubMedPubMedCentralCrossRef

Park, M. J., Aja, S., Li, Q., Degano, A. L., Penati, J., Zhuo, J., et al. (2014). Anaplerotic triheptanoin diet enhances mitochondrial substrate use to remodel the metabolome and improve lifespan, motor function, and sociability in MeCP2-null mice. PLoS ONE,9(10), e109527. https://doi.org/10.1371/journal.pone.0109527.PubMedPubMedCentralCrossRef

Patrizi, A., Picard, N., Simon, A. J., Gunner, G., Centofante, E., Andrews, N. A., et al. (2016). Chronic administration of the N-methyl-D-aspartate receptor antagonist ketamine improves Rett syndrome phenotype. Biological Psychiatry,79(9), 755–764. https://doi.org/10.1016/j.biopsych.2015.08.018.PubMedCrossRef

Pecorelli, A., Cervellati, C., Hayek, J., & Valacchi, G. (2017). Modulation of oxidative stress response in neurodevelopment disorders. The case of the Rett syndrome variants: MECP2 and CDKL5. Free Radical Biology and Medicine,108, S43.CrossRef

Percy, A., Glaze, D. G., Neul, J. L., Kaufmann, W. E., Berry-Kravis, E., Condon, S., et al. (2017). 1.49 Trofinetide, a novel IGF-1 related treatment for neurodevelopmental disorders, demonstrates efficacy for children and adolescents with Rett syndrome. Journal of the American Academy of Child & Adolescent Psychiatry, 56(10), S168–S169. https://doi.org/10.1016/j.jaac.2017.09.063

Percy, A. K., Glaze, D. G., Schultz, R. J., Zoghbi, H. Y., Williamson, D., Frost, J. D., et al. (1994). Rett syndrome: Controlled study of an oral opiate antagonist, naltrexone. Annals of Neurology,35(4), 464–470. https://doi.org/10.1002/ana.410350415.PubMedCrossRef

Pini, G., Congiu, L., Benincasa, A., DiMarco, P., Bigoni, S., Dyer, A. H., et al. (2016). Illness severity, social and cognitive ability, and EEG analysis of ten patients with Rett syndrome treated with mecasermin (recombinant human IGF-1). Autism Research and Treatment,2016, 1–9. https://doi.org/10.1155/2016/5073078.CrossRef

Pini, G., Scusa, M. F., Benincasa, A., Bottiglioni, I., Congiu, L., Vadhatpour, C., et al. (2014). Repeated insulin-like growth factor 1 treatment in a patient with rett syndrome: A single case study. Frontiers in Pediatrics,2, 52. https://doi.org/10.3389/fped.2014.00052.PubMedPubMedCentralCrossRef

Pini, G., Scusa, M. F., Congiu, L., Benincasa, A., Morescalchi, P., Bottiglioni, I., et al. (2012). IGF1 as a potential treatment for Rett syndrome: Safety assessment in six Rett patients. Autism Research and Treatment,2012, 1–14. https://doi.org/10.1155/2012/679801.CrossRef

Pitcher, M. R., Herrera, J. A., Buffington, S. A., Kochukov, M. Y., Merritt, J. K., Fisher, A. R., et al. (2015). Rett syndrome like phenotypes in the R255X Mecp2 mutant mouse are rescued by MECP2 transgene. Human Molecular Genetics,24(9), 2662–2672.PubMedPubMedCentralCrossRef

Pitcher, M. R., Ward, C. S., Arvide, E. M., Chapleau, C. A., Pozzo-Miller, L., Hoeflich, A., et al. (2013). Insulinotropic treatments exacerbate metabolic syndrome in mice lacking MeCP2 function. Human Molecular Genetics,22(13), 2626–2633.PubMedPubMedCentralCrossRef

Popescu, A. C., Sidorova, E., Zhang, G., & Eubanks, J. H. (2010). Aminoglycoside-mediated partial suppression of MECP2 nonsense mutations responsible for Rett syndrome in vitro. Journal of Neuroscience Research,88(11), 2316–2324.PubMed

Reichow, B., George-Puskar, A., Lutz, T., Smith, I. C., & Volkmar, F. R. (2015). Brief report: Systematic review of Rett syndrome in males. Journal of Autism and Developmental Disorders,45(10), 3377–3383. https://doi.org/10.1007/s10803-015-2519-1.PubMedCrossRef

Rett, A. (1966). [On a unusual brain atrophy syndrome in hyperammonemia in childhood]. Wiener Medizinische Wochenschrift (1946), 116(37), 723–726.

Ricceri, L., De Filippis, B., Fuso, A., & Laviola, G. (2011). Cholinergic hypofunction in MeCP2-308 mice: Beneficial neurobehavioural effects of neonatal choline supplementation. Behavioural Brain Research,221(2), 623–629. https://doi.org/10.1016/j.bbr.2011.03.051.PubMedCrossRef

Robinson, L., Guy, J., McKay, L., Brockett, E., Spike, R. C., Selfridge, J., et al. (2012). Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome. Brain: A Journal of Neurology, 135(Pt 9), 2699–2710. https://doi.org/10.1093/brain/aws096

Roux, J.-C., Dura, E., Moncla, A., Mancini, J., & Villard, L. (2007). Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome. The European Journal of Neuroscience,25(7), 1915–1922. https://doi.org/10.1111/j.1460-9568.2007.05466.x.PubMedCrossRef

Roux, J.-C., Zala, D., Panayotis, N., Borges-Correia, A., Saudou, F., & Villard, L. (2012). Modification of Mecp2 dosage alters axonal transport through the Huntingtin/Hap1 pathway. Neurobiology of Disease,45(2), 786–795.PubMedCrossRef

Schaevitz, L. R., Nicolai, R., Lopez, C. M., D’Iddio, S., Iannoni, E., & Berger-Sweeney, J. E. (2012). Acetyl-L-carnitine improves behavior and dendritic morphology in a mouse model of Rett syndrome. PLoS ONE,7(12), e51586. https://doi.org/10.1371/journal.pone.0051586.PubMedPubMedCentralCrossRef

Schmid, D. A., Yang, T., Ogier, M., Adams, I., Mirakhur, Y., Wang, Q., et al. (2012). A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome. Journal of Neuroscience,32(5), 1803–1810.PubMedCrossRef

Segawa, M. (2001). Pathophysiology of Rett syndrome from the stand point of clinical characteristics. Brain and Development,23, S94–S98.PubMedCrossRef

Shapiro, J. R., Boskey, A. L., Doty, S. B., Lukashova, L., & Blue, M. E. (2017). Zoledronic acid improves bone histomorphometry in a murine model of Rett syndrome. Bone,99, 1–7. https://doi.org/10.1016/j.bone.2017.03.040.PubMedCrossRef

Sheikh, A. (2016). Pre-clinical study of NLX-101 for the treatment of apnoeas in two mouse models of Rett syndrome. Presented at the Pharmacology, London, UK. https://www.pa2online.org/abstracts/vol16issue1abst027p.pdf. Accessed 3 Jan 2019

Sheikh, A. (2017). NLX-101 ameliorates responses to hypercapnia in a mouse model of Rett syndrome. Presented at the Pharmacology 2017, London, UK. https://www.pa2online.org/abstracts/vol18issue1abst139p.pdf. Accessed 3 Jan 2019

Shulyakova, N. O. (2016). Studies of mitochondrial dysfunction in models of Rett syndrome (PhD Thesis).

Simacek, J., Dimian, A. F., & McComas, J. J. (2017). Communication intervention for young children with severe neurodevelopmental disabilities via telehealth. Journal of Autism and Developmental Disorders,47(3), 744–767. https://doi.org/10.1007/s10803-016-3006-z.PubMedPubMedCentralCrossRef

Smeets, E. E. J., Pelc, K., & Dan, B. (2011). Rett syndrome Molecular Syndromology,2(3–5), 113–127. https://doi.org/10.1159/000337637.CrossRef

Smith-Hicks, C. L., Gupta, S., Ewen, J. B., Hong, M., Kratz, L., Kelley, R., et al. (2017). Randomized open-label trial of dextromethorphan in Rett syndrome. Neurology,89(16), 1684–1690. https://doi.org/10.1212/WNL.0000000000004515.PubMedPubMedCentralCrossRef

Specchio, N., Balestri, M., Striano, P., Cilio, M. R., Nardello, R., Patanè, S., et al. (2010). Efficacy of levetiracetam in the treatment of drug-resistant Rett syndrome. Epilepsy Research,88(2–3), 112–117. https://doi.org/10.1016/j.eplepsyres.2009.10.005.PubMedCrossRef

Stenbom, Y., Tonnby, B., & Hagberg, B. (1998). Lamotrigine in Rett syndrome: treatment experience from a pilot study. European Child & Adolescent Psychiatry,7(1), 49–52.CrossRef

Strebl, M. G., Campbell, A. J., Zhao, W.-N., Schroeder, F. A., Riley, M. M., Chindavong, P. S., et al. (2017). HDAC6 brain mapping with [18F]Bavarostat enabled by a Ru-mediated deoxyfluorination. ACS Central Science,3(9), 1006–1014. https://doi.org/10.1021/acscentsci.7b00274.PubMedPubMedCentralCrossRef

Szczesna, K., de la Caridad, O., Petazzi, P., Soler, M., Roa, L., Saez, M. A., et al. (2014). Improvement of the Rett syndrome phenotype in a MeCP2 mouse model upon treatment with levodopa and a dopa-decarboxylase inhibitor. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 39(12), 2846–2856. https://doi.org/10.1038/npp.2014.136

Tao, J., Wu, H., Coronado, A. A., de Laittre, E., Osterweil, E. K., Zhang, Y., et al. (2016). Negative allosteric modulation of mGluR5 partially corrects pathophysiology in a mouse model of Rett syndrome. The Journal of Neuroscience,36(47), 11946–11958. https://doi.org/10.1523/JNEUROSCI.0672-16.2016.PubMedPubMedCentralCrossRef

Titlestad, K. B., & Eldevik, S. (2019). Brief report: Modest but clinically meaningful effects of early behavioral intervention in twins with Rett syndrome—A case study. Journal of Autism and Developmental Disorders. https://doi.org/10.1007/s10803-019-04185-9.PubMedCrossRef

Toward, M. A., Abdala, A. P., Knopp, S. J., Paton, J. F. R., & Bissonnette, J. M. (2013). Increasing brain serotonin corrects CO₂ chemosensitivity in methyl-CpG-binding protein 2 (Mecp2)-deficient mice. Experimental Physiology,98(3), 842–849. https://doi.org/10.1113/expphysiol.2012.069872.PubMedCrossRef

Tropea, D., Giacometti, E., Wilson, N. R., Beard, C., McCurry, C., Fu, D. D., et al. (2009). Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proceedings of the National Academy of Sciences,106(6), 2029–2034.CrossRef

Uldall, P., Hansen, F. J., & Tonnby, B. (1993). Lamotrigine in Rett syndrome. Neuropediatrics,24(6), 339–340. https://doi.org/10.1055/s-2008-1071568.PubMedCrossRef

Valacchi, G., Virgili, F., Cervellati, C., & Pecorelli, A. (2018). OxInflammation: From subclinical condition to pathological biomarker. Frontiers in Physiology. https://doi.org/10.3389/fphys.2018.00858.PubMedPubMedCentralCrossRef

Valenti, D., de Bari, L., Vigli, D., Lacivita, E., Leopoldo, M., Laviola, G., et al. (2017). Stimulation of the brain serotonin receptor 7 rescues mitochondrial dysfunction in female mice from two models of Rett syndrome. Neuropharmacology,121, 79–88. https://doi.org/10.1016/j.neuropharm.2017.04.024.PubMedCrossRef

Vashi, N., & Justice, M. J. (2019). Treating Rett syndrome: from mouse models to human therapies. Mammalian Genome,30(5), 90–110. https://doi.org/10.1007/s00335-019-09793-5.PubMedPubMedCentralCrossRef

Vecsler, M., Zeev, B. B., Nudelman, I., Anikster, Y., Simon, A. J., Amariglio, N., et al. (2011). Ex vivo treatment with a novel synthetic aminoglycoside NB54 in primary fibroblasts from Rett syndrome patients suppresses MECP2 nonsense mutations. PLoS ONE,6(6), e20733.PubMedPubMedCentralCrossRef

Venugopal, A., Chandran, M., Eruppakotte, N., Kizhakkillach, S., Breezevilla, S. C., & Vellingiri, B. (2018). Monogenic diseases in India. Mutation Research,776, 23–31. https://doi.org/10.1016/j.mrrev.2018.03.003.PubMedCrossRef

Vigli, D., Cosentino, L., Raggi, C., Laviola, G., Woolley-Roberts, M., & De Filippis, B. (2018). Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome. Neuropharmacology,140, 121–129. https://doi.org/10.1016/j.neuropharm.2018.07.029.PubMedCrossRef

Vignoli, A., Savini, M. N., Nowbut, M. S., Peron, A., Turner, K., La Briola, F., et al. (2017). Effectiveness and tolerability of antiepileptic drugs in 104 girls with Rett syndrome. Epilepsy & Behavior: E&B,66, 27–33. https://doi.org/10.1016/j.yebeh.2016.10.006.CrossRef

Villani, C., Sacchetti, G., Bagnati, R., Passoni, A., Fusco, F., Carli, M., & Invernizzi, R. W. (2016). Lovastatin fails to improve motor performance and survival in methyl-CpG-binding protein2-null mice. eLife. https://doi.org/10.7554/eLife.22409

Wang, D., Belakhov, V., Kandasamy, J., Baasov, T., Li, S.-C., Li, Y.-T., et al. (2012). The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS IH in the Idua-W392X mouse. Molecular genetics and metabolism,105(1), 116–125.PubMedCrossRef

Ward, B. C., Agarwal, S., Wang, K., Berger-Sweeney, J., & Kolodny, N. H. (2008). Longitudinal brain MRI study in a mouse model of Rett syndrome and the effects of choline. Neurobiology of Disease,31(1), 110–119. https://doi.org/10.1016/j.nbd.2008.03.009.PubMedCrossRef

Wiedemann, A., Renard, E., Hernandez, M., Dousset, B., Brezin, F., Lambert, L., et al. (2018). Annual injection of zoledronic acid improves bone status in children with cerebral palsy and Rett syndrome. Calcified Tissue International. https://doi.org/10.1007/s00223-018-0505-2.PubMedCrossRef

Xu, X., Kozikowski, A. P., & Pozzo-Miller, L. (2014). A selective histone deacetylase-6 inhibitor improves BDNF trafficking in hippocampal neurons from Mecp2 knockout mice: implications for Rett syndrome. Frontiers in Cellular Neuroscience,8, 68. https://doi.org/10.3389/fncel.2014.00068.PubMedPubMedCentralCrossRef

Yu, D., Sakurai, F., & Corey, D. R. (2011). Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression. Bioorganic & Medicinal Chemistry Letters,21(18), 5202–5205. https://doi.org/10.1016/j.bmcl.2011.07.053.CrossRef

Zanella, S., Mebarek, S., Lajard, A.-M., Picard, N., Dutschmann, M., & Hilaire, G. (2008). Oral treatment with desipramine improves breathing and life span in Rett syndrome mouse model. Respiratory Physiology & Neurobiology, 160(1), 116–121. https://doi.org/10.1016/j.resp.2007.08.009.CrossRef

Zhang, S., & Zhang, Z.-Y. (2007). PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Discovery Today,12(9–10), 373–381. https://doi.org/10.1016/j.drudis.2007.03.011.PubMedCrossRef

Zhong, W., Johnson, C. M., Wu, Y., Cui, N., Xing, H., Zhang, S., et al. (2016). Effects of early-life exposure to THIP on phenotype development in a mouse model of Rett syndrome. Journal of Neurodevelopmental Disorders,8, 37. https://doi.org/10.1186/s11689-016-9169-2.PubMedPubMedCentralCrossRef

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 8/2020

Family Sexuality Communication: Parent Report for Autistic Young Adults Versus a Comparison Group

Pain Modulation Mechanisms in ASD Adults

No Differences in Code-Related Emergent Literacy Skills in Well-Matched 4-Year-Old Children With and Without ASD

Symbolic Understanding and Word–Picture–Referent Mapping from iPads in Autism Spectrum Condition: The Roles of Iconicity and Engagement

Altered GABA Concentration in Brain Motor Area Is Associated with the Severity of Motor Disabilities in Individuals with Autism Spectrum Disorder

Impact of Selective Eating on Social Domains Among Transition-Age Youth with Autism Spectrum Disorder: A Qualitative Study